Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RX-0201 + everolimus
- Development stage
- Unknown
- Lead developer
- Rexahn Pharmaceuticals
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous (for RX-0201), Oral (for Everolimus)
01
Overview
RX-0201 + everolimus is an investigational combination therapy consisting of RX-0201 (also known as Archexin), a 20-mer antisense oligonucleotide that binds AKT-1 mRNA, thereby inhibiting AKT-1 protein expression, and everolimus, an oral inhibitor of the mammalian target of rapamycin complex 1 (mTORC1). RX-0201 downregulates the PI3K/AKT pathway, and everolimus inhibits mTOR, a downstream effector in this pathway. The combination is designed to target the AKT-1/mTOR pathway synergistically to inhibit cancer cell proliferation and survival. This combination has primarily been evaluated in metastatic renal cell carcinoma (mRCC) in patients who previously progressed on VEGFR inhibitors, with early clinical studies demonstrating tolerable safety and promising clinical activity[1][5][3]. RX-0201 was developed by Rexahn Pharmaceuticals.
- Brand names
- Archexin (for RX-0201)RX-0201 + everolimus
- Other names
- RX-0201 nanoliposomal + everolimusAKT-1 antisense oligonucleotide + everolimus
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on RX-0201 + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RX-0201 + everolimus.